Fierce Biotech1d
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
Yahoo Finance15d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
Seeking Alpha15d
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal ...
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss treatment. The current generation, made up of blockbuster drugs like Wegovy and ...
24/7 Wall St.6d
Novo Nordisk (NVO) Price Prediction and Forecast 2025-2030 (March 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk expands discounted Wegovy to all cash-paying US customers
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...
FINAL NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Novo Nordisk A/S Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Germany’s SAP Overtakes Wegovy Maker Novo Nordisk as Europe’s Most Valuable Company
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...